03 Postdoctoral Fellowship at Masaryk University, Czech Republic

Antimicrobial peptides (AMPs) possess the ability to disrupt the membrane barrier function, effectively eliminating bacteria, viruses, and even cancer cells. Consequently, AMPs have emerged as promising candidates for the development of a new class of therapeutics. However, the majority of known AMPs exhibit toxic properties due to their origin from human-unfriendly sources, such as venoms. Furthermore, our understanding of peptide targeting mechanisms towards specific pathogens and their membranes remains limited, hindering further advancements in this field. This ERC funded project aims to identify peptide sequence motifs that are responsible for targeting pathogens, while maintaining minimal toxicity towards human cells. In conjunction with the lipid composition of membranes, we will investigate the impact of membrane local curvature. The main tool will be Molecular dynamics simulations with free energy calculations using Gromacs program package. These simulations will be complemented by in-house experiments providing crucial verification and feedback on peptide-membrane affinity. The acquired knowledge will guide the design of de novo peptides with enhanced pathogen-targeting specificity.

A post-doctoral position is open in the lab of Dr. Michal Šmída (https://www.ceitec.eu/ceitec-mu/michal-smida-research-group/rg214) to participate in research focused on the identification of novel targets for therapy of leukemias, particularly acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). The research group is investigating molecular mechanisms essential for malignant cells and/or responsible for developing resistance to current targeted therapies. More importantly, we explore how to exploit the resistance mechanisms for novel personalized therapy. We are seeking a talented person with expertise in cell biology, molecular biology and biochemistry to perform various large-scale drug screens and genome-wide CRISPR/Cas9 cellular screens with following in-depth validation of the screening hits and detailed elucidation of molecular mechanisms. The aim of the project will be to propose novel molecular targets to break the therapy resistance and thereby enhance the success rate of the therapy in CLL or AML patients. The project will include translational research using immortalized cell lines, mouse models and primary patient material. State-of-the-art technologies such as genome-wide CRISPR/Cas9 screening, next-generation sequencing or single-cell sequencing are available in the laboratory and/or local core facilities, and are accessible on a regular basis. We are seeking a creative, independent and driven individual with documented research experience related to this position. Candidates with strong research experience in cancer biology and personalized medicine are encouraged to apply.